Background: AGI-1096 is a novel phenolic intracellular antioxidant with anti-inflammatory and antiproliferative properties. In vitro, AGI-1096 inhibited the inducible expression of vascular cell adhesion molecule (VCAM)-1, E-selectin, and monocyte chemoattractant protein (MCP)-1 in endothelial cells and tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta secretion from lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells. It also inhibited serum-stimulated proliferation of aortic smooth-muscle cells. In vivo, AGI-1096 demonstrated anti-inflammatory properties in a murine delayed-type hypersensitivity model. Given these antioxidant, anti-inflammatory and antiproliferative properties, we reasoned that AGI-1096 may be able to prevent chronic allograft arteriosclerosis. This hypothesis was tested in a rodent aortic transplantation model.

Methods: Donor descending aortas from August-Copenhagen-Irish rats were heterotopically transplanted into Lewis rat abdomens in end-to-end fashion. Animals were assigned to six groups as follows: AGI-1096 0 mg/kg per day (vehicle, n = 10), 10 mg/kg per day (n = 10), 20 mg/kg per day (n = 10), 40 mg/kg per day (n = 10), positive control (cyclosporine A 10 mg/kg per day by oral gavage, n = 10), and isograft negative control (Lewis-to-Lewis, n = 5). AGI-1096 was administrated subcutaneously to recipient animals three days before the surgery and for 90 days thereafter. On day 90, the paraffin-embedded allograft sections were stained with Elastin-van Gieson's stain, and the intima/media (I/M) ratio and luminal narrowing (1%LN) was assessed by digital morphometry.

Results: AGI-1096 demonstrated dose-dependent lowering of the I/M ratio and %LN when compared with vehicle controls.

Conclusion: This is the first study to show that treatment of allograft recipients with AGI-1096 decreases the incidence of transplant arteriosclerosis. These data suggest that AGI-1096 may be a promising new therapeutic agent for use in clinical transplantation.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.tp.0000123076.05313.9fDOI Listing

Publication Analysis

Top Keywords

mg/kg day
20
anti-inflammatory antiproliferative
12
antiproliferative properties
12
agi-1096
9
agi-1096 novel
8
allograft arteriosclerosis
8
antioxidant anti-inflammatory
8
agi-1096 demonstrated
8
day mg/kg
8
i/m ratio
8

Similar Publications

EVALUATION OF THE EFFECTS OF FAVIPIRAVIR (T-705) ON THE LUNG TISSUE OF HEALTY RATS: AN EXPERIMENTAL STUDY.

Food Chem Toxicol

January 2025

Department of Histology and Embryology, Erciyes University, Faculty of Medicine, 38039 Kayseri, Turkey. Electronic address:

Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor widely used during the COVID-19 pandemic, effectively reduces viral load but has been linked to inflammatory changes in tissues such as the liver and kidneys. High-dose and prolonged use of favipiravir for COVID-19 raises concerns about its potential toxic effects on the lungs, particularly in patients with pre-existing pulmonary conditions. This study investigated favipiravir's effects on lung tissue in healthy rats.

View Article and Find Full Text PDF

IGSF8 impairs migration and invasion of trophoblast cells and angiogenesis in preeclampsia.

Exp Cell Res

January 2025

Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China. Electronic address:

Insufficient trophoblast cell infiltration is implicated in the progression of preeclampsia (PE). The immunoglobulin superfamily member 8 (IGSF8) has been shown to promote cell migration, invasion, and epithelial mesenchymal transition (EMT). However, the specific impact of IGSF8 on trophoblast cells in PE has not been definitively demonstrated.

View Article and Find Full Text PDF

Ethnopharmacological Relevance: Dihuang Drink (DHD), formulated by Liu Hejian during the Yuan Dynasty, is listed as one of the first ancient classical prescriptions by the National Medical Products Administration of China. It is commonly used for the prevention and treatment of Alzheimer's disease (AD). This study further investigates the therapeutic effects and potential mechanisms of DHD in AD.

View Article and Find Full Text PDF

Introduction: The phase 2 TROPiCS-03 study evaluated the efficacy/safety of sacituzumab govitecan (SG) as second-line treatment in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC).

Methods: TROPiCS-03 (NCT03964727) is a multicohort, open-label, phase 2 basket study in solid tumors, including ES-SCLC. Adults with ES-SCLC that progressed after one prior line of platinum-based chemotherapy and anti-programmed death-(ligand) 1 (PD-[L]1) therapy received SG 10 mg/kg on days 1 and 8 of a 21-day cycle.

View Article and Find Full Text PDF

Maternal exposure to polystyrene nanoplastics during gestation and lactation caused fertility decline in female mouse offspring.

Ecotoxicol Environ Saf

January 2025

School of Public Health, Jiangxi Medical College, Nanchang University; Jiangxi Provincial Key Laboratory of Disease Prevention and Public Health, Nanchang University, Nanchang 330006, China; Department of Reproductive Medicine, the 1st affiliated hospital, Jiangxi Medical College, Nanchang University; Jiangxi Key Laboratory of Reproductive Health, Nanchang 330006, China; HuanKui College, Nanchang University, Nanchang 330031, China; Chongqing Research Institute of Nanchang University, Nanchang University, Nanchang 330006, China. Electronic address:

The impact of micro/nano plastics (MPs/NPs) on human health is a significant area of research. Studies on the effects of maternal exposure to microplastics (MPs) on the fertility in offspring have been conducted, but the damage caused by nanoplastics (NPs) remains ambiguous. In this study, pregnant Kunming mice were exposed to 30 mg/kg/day PS-NPs from 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!